Comparative Oncology Today

Veterinary Clinics of North America - Small Animal Practice

Volumn 37, Issue 6, 2007, Pages 1023-1032

  Paoloni, Melissa C ^a   Khanna, Chand ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; MITOXANTRONE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

AGE; ANIMAL CARE; BACTERIOPHAGE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER INCIDENCE; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MARKER; DNA MICROARRAY; DOG DISEASE; DRUG SPECIFICITY; DRUG TREATMENT FAILURE; ENVIRONMENTAL EXPOSURE; GENE SEQUENCE; GENE TARGETING; GENETIC SIMILARITY; GENOMICS; HEAD AND NECK CARCINOMA; LEUKEMIA; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUTRITION; OSTEOSARCOMA; PROSTATE CARCINOMA; REPRODUCTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DOG DISEASES; DOGS; MEDICAL ONCOLOGY; NEOPLASMS; SPECIES SPECIFICITY; VETERINARY MEDICINE;

CANIS FAMILIARIS;

EID: 35348812507     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.08.003     Document Type: Review

References (62)

1. Khanna C., Lindblad-Toh K., Vail D., et al. The dog as a cancer model. Nat Biotechnol 24 9 (2006) 1065-1066
2. Vail D.M., and MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18 8 (2000) 781-792
3. Hansen K., and Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40 6 (2004) 858-880
4. Withrow S.J., and Vail D.M. Withrow & MacEwen's small animal clinical oncology. 4th edition (2007), Saunders Elsevier, St. Louis (MO)
5. Antinoff N., and Hahn K. Ferret oncology: diseases, diagnostics, and therapeutics. Vet Clin North Am Exot Anim Pract 7 3 (2004) 579-625 vi
6. Olson P.N. Using the canine genome to cure cancer and other diseases. Theriogenology 68 3 (2007) 378-381
7. Naylor R.J., and Rudd J.A. Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Oncology 53 Suppl 1 (1996) 8-17
8. Bukowski J.A., Wartenberg D., and Goldschmidt M. Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. J Toxicol Environ Health A 54 7 (1998) 579-591
9. Hahn K.A., Bravo L., Adams W.H., et al. Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8 1 (1994) 133-143
10. Mutsaers A.J., Widmer W.R., and Knapp D.W. Canine transitional cell carcinoma. J Vet Intern Med 17 2 (2003) 136-144
11. Rusk A., McKeegan E., Haviv F., et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12 24 (2006) 7444-7455
12. Rusk A., Cozzi E., Stebbins M., et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 12 24 (2006) 7456-7464
13. Thamm D.H., Kurzman I.D., King I., et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 11 13 (2005) 4827-4834
14. Buchholz J., Kaser-Hotz B., Khan T., et al. Optimizing photodynamic therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Clin Cancer Res 11 20 (2005) 7538-7544
15. Vail D.M., Amantea M.A., Colbern G.T., et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31 6 Suppl 13 (2004) 16-35
16. London C.A., Hannah A.L., Zadovoskaya R., et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9 7 (2003) 2755-2768
17. Khanna C., and Vail D.M. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 3 4 (2003) 265-273
18. Khanna C., Prehn J., Hayden D., et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 8 7 (2002) 2406-2412
19. MacEwen E.G., Kurzman I.D., Vail D.M., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 12 (1999) 4249-4258
20. Hershey A.E., Kurzman I.D., Forrest L.J., et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5 9 (1999) 2653-2659
21. Khanna C., Waldrep J.C., Anderson P.M., et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 49 10 (1997) 960-971
22. Vail D.M., MacEwen E.G., Kurzman I.D., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1 10 (1995) 1165-1170
23. Kurzman I.D., MacEwen E.G., Rosenthal R.C., et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1 12 (1995) 1595-1601
24. Kurzman I.D., Cheng H., and MacEwen E.G. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity. Cancer Biother 9 2 (1994) 113-121
25. Withrow S.J., Thrall D.E., Straw R.C., et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71 8 (1993) 2484-2490
26. LaRue S.M., Withrow S.J., Powers B.E., et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 195 12 (1989) 1734-1744
27. Elmslie R.E., and Dow S.W. Genetic immunotherapy for cancer. Semin Vet Med Surg (Small Anim) 12 3 (1997) 193-205
28. Dow S.W., and Potter T.A. Expression of bacterial superantigen genes in mice induces localized mononuclear cell inflammatory responses. J Clin Invest 99 11 (1997) 2616-2624
29. Sutter N.B., Bustamante C.D., Chase K., et al. A single IGF1 allele is a major determinant of small size in dogs. Science 316 5821 (2007) 112-115
30. Patrick D.J., Fitzgerald S.D., Sesterhenn I.A., et al. Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification. J Comp Pathol 135 4 (2006) 190-199
31. Ostrander E.A., Giger U., and Lindblad-Toh K. The dog and its genome (2006), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY)
32. Thomas R., Scott A., Langford C.F., et al. Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res 15 12 (2005) 1831-1837
33. Lindblad-Toh K., Wade C.M., Mikkelsen T.S., et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438 7069 (2005) 803-819
34. Lee C.H., Kim W.H., Lim J.H., et al. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 5 1 (2004) 63-69
35. Jones C.L., Grahn R.A., Chien M.B., et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 16 2 (2004) 95-100
36. Thomas R., Smith K.C., Ostrander E.A., et al. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer 89 8 (2003) 1530-1537
37. Pryer N.K., Lee L.B., Zadovaskaya R., et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 9 15 (2003) 5729-5734
38. Lingaas F., Comstock K.E., Kirkness E.F., et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet 12 23 (2003) 3043-3053
39. Ozaki K., Yamagami T., Nomura K., et al. Mast cell tumors of the gastrointestinal tract in 39 dogs. Vet Pathol 39 5 (2002) 557-564
40. Lee C.H., and Kweon O.K. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 3 4 (2002) 321-325
41. Wakui S., Muto T., Yokoo K., et al. Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Res 21 1B (2001) 611-616
42. Setoguchi A., Sakai T., Okuda M., et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res 62 3 (2001) 433-439
43. Reguera M.J., Rabanal R.M., Puigdemont A., et al. Canine mast cell tumors express stem cell factor receptor. Am J Dermatopathol 22 1 (2000) 49-54
44. London C.A., Galli S.J., Yuuki T., et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 27 4 (1999) 689-697
45. Van Leeuwen I.S., Hellmen E., Cornelisse C.J., et al. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res 16 6B (1996) 3737-3744
46. London C.A., Kisseberth W.C., Galli S.J., et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 115 4 (1996) 399-414
47. Hayes Jr. H.M., and Fraumeni Jr. J.F. Epidemiological features of canine renal neoplasms. Cancer Res 37 8 Pt 1 (1977) 2553-2556
48. Modiano J.F., Breen M., Burnett R.C., et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 65 13 (2005) 5654-5661
49. Kiupel M., Webster J.D., Kaneene J.B., et al. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 41 4 (2004) 371-377
50. Olson P.N. Fighting cancer in dogs. J Am Vet Med Assoc 230 9 (2007) 1280-1297
51. Porrello A., Cardelli P., and Spugnini E.P. Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25 1 (2006) 97-105
52. Lana S., Plaza S., Hampe K., et al. Diagnosis of mediastinal masses in dogs by flow cytometry. J Vet Intern Med 20 5 (2006) 1161-1165
53. Lana S.E., Jackson T.L., Burnett R.C., et al. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J Vet Intern Med 20 2 (2006) 329-334
54. Proschowsky H.F., Rugbjerg H., and Ersboll A.K. Mortality of purebred and mixed-breed dogs in Denmark. Prev Vet Med 58 1-2 (2003) 63-74
55. MacEwen E.G., Kurzman I.D., Helfand S., et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target 2 5 (1994) 391-396
56. Kamb A., Wee S., and Lengauer C. Why is cancer drug discovery so difficult?. Nat Rev Drug Discov 6 2 (2007) 115-120
57. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3 8 (2004) 711-715
58. Available at: www.acvim.org.
59. Available at: www.acvr.org.
60. Available at: www.vetcancersociety.org.
61. Available at: ccr.cancer.gov/resources/cop/scientists/resource_genomics.asp.
62. Available at: ccr.cancer.gov/resources/cop.